

He lung, cystic fibrosis (mucoviscidosis), glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative, a plant extract containing boswellic acid, or combinations thereof, in an amount effective for treating the destruction of functional tissue, to combat said diseases to a mammalian organism in need of such combating.

---

18. (Amended) The method as claimed in claim 28, wherein said boswellic acid is administered intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, intraarticularly, intravenously or inhalationally.

19. (Amended) The method as claimed in claim 28, wherein said boswellic acid is administered in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.

20. (Amended) The method as claimed in claim 28, wherein said mammalian organism is an animal.

21. (Amended) The method as claimed in claim 28, wherein said mammalian organism is a human.

112 22. (Amended) The method as claimed in claim 28, wherein a pharmaceutical compound is also present.

---

28. (Amended) A method for treating the destruction of functional tissue associated with diseases selected from the group consisting of pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative, a plant extract containing boswellic acid, or combinations thereof, in an amount effective for treating the destruction of functional tissue, to a mammalian organism in need of such treatment.

113 29. (Amended) A method for treating the destruction of functional tissue associated with tumors and neoplasms or tumor metastases which are caused by increased plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, said method comprising administering boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative, a plant extract containing boswellic acid, or combinations thereof, in an amount effective for treating the destruction of functional tissue, to a mammalian organism in need of such treatment.

---

Please add the following new claims.

30. (New) The method as claimed in claim 29, wherein said boswellic acid is administered intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, intraarticularly, intravenously or inhalationally.

31. (New) The method as claimed in claim 29, wherein said boswellic acid is administered in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.

32. (New) The method as claimed in claim 29, wherein said mammalian organism is an animal.

33. (New) The method as claimed in claim 29, wherein said mammalian organism is a human.

34. (New) The method as claimed in claim 29, wherein a pharmaceutical compound is also present.

35. (New) The method as claimed in claim 29, wherein said plant preparation is obtained from resin.

36. (New) The method as claimed in claim 29, wherein the effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a

plant preparation containing boswellic acid is administered together with a pharmaceutical compound.

37. (New) The method as claimed in claim 29, wherein said plant extract is an olibanum extract.

38. (New) The method as claimed in claim 28, wherein said plant preparation is obtained from resin.

39. (New) The method as claimed in claim 28, wherein the effective amount of boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid is administered together with a pharmaceutical compound.

40. (New) The method as claimed in claim 28, wherein said plant extract is an olibanum extract.

---